

PATIENT FAX ALERT



WellCare Health Plans, Inc.

****ATTACH TO PATIENT'S CHART****

Physician: _____ Today's Date: _____
Patient: _____ Admitted To: _____
Member ID: _____ Admit Date: _____
Diagnosis: _____ Discharge Date: _____

This member was recently hospitalized. If you are considering a therapeutic trial of an inhaled corticosteroid, please refer to our applicable preferred drug list below.

Preferred Drug List:

Short Acting Beta 2- Adrenergic Agonist Bronchodilators: albuterol, terbutaline, metaproterenol, Maxair®, Ventolin® HFA

Inhaled Corticosteroids: Asmanex®, Flovent®, Qvar®

Leukotriene Modifiers: Singulair®

Other anti-inflammatory inhalers: Intal®, Tilade®

Theophyllines & Aminophylline: Theodur®, Uniphyl®, and Aminophylline

Long-Acting Bronchodilators: Serevent Diskus®

Combination Corticosteroid and Long Acting Bronchodilator: Advair®, Symbicort®

Peak Flow Meters:

Medicaid members can obtain peak flow meters with a prescription at their local pharmacy.

Spacers:

Medicaid members can obtain spacers, i.e. Aerochamber, EZY Spacers®, Microspacers®, with a prescription at their local pharmacy.

***Note medication coverage is subject to generic, brand, and co-pay benefit structure.**

NAEPP Guidelines* for the management of Asthma recommend:

- Inhaled corticosteroids are safe, effective and preferred first-line therapy for children as well as adults with persistent asthma.
- Leukotriene modifiers and other anti-inflammatory agents are alternatives for mild persistent asthma.
- Theophylline can reduce frequency and severity of persistent symptoms
- Adding a long-acting inhaled Beta 2-agonist to inhaled steroids is more effective than simply increasing the dose of inhaled steroids for patients over 5 years old who have moderate to persistent asthma.
- Short acting inhaled Beta 2-agonists are the most effective drugs for treatment of breakthrough symptoms and immediate prevention of exercise-induced asthma.

* Expert Panel Report: Guidelines for the diagnosis and management of Asthma. Update on selected topics 2002. National Heart, Lung, and Blood Institute. NIH Publication No. 02-5074 June 2003.

Address questions to our Asthma Disease Management Program 1-866-593-2538.

PRIVACY NOTICE: This facsimile message and any attachment is intended for the exclusive use of the addressee(s) and may contain information that is proprietary, confidential and/or exempt from disclosure and may be Protected Health Information. If you are not the intended recipient, please notify us immediately by calling the number below and return the original message to us at the address below via the US Postal Service. We will reimburse you for your postage. If you are a regular recipient of our faxes, please notify us if you change your fax number.